Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

In a release issued under the same headline earlier today by HPQ Silicon Inc. , please note that in the 11th paragraph, the number of units issued is not 1,009,343 but 1,083,333. The revised release ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Dr. McClure's distinguished track record in designing and directing successful early-to-late-stage clinical trials, which include several marketed products, further demonstrates Lifordi's commitment ...

This year's 10 most-read Chicago Inno stories were dominated by new developments and recent funding rounds, along with one ...

Arthur J. Gallagher & Co. today announced the acquisition of Tustin, California-based Murray Gardner Insurance Agency Inc., dba BMR Insurance. Terms of the transaction were not ...